DexComDXCM
About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 9,600
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
5% less call options, than puts
Call options by funds: $405M | Put options by funds: $424M
6% less repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 344
7.55% less ownership
Funds ownership: 96.97% [Q2] → 89.41% (-7.55%) [Q3]
12% less funds holding
Funds holding: 982 [Q2] → 869 (-113) [Q3]
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
45% less capital invested
Capital invested by funds: $43.7B [Q2] → $24B (-$19.7B) [Q3]
51% less first-time investments, than exits
New positions opened: 98 | Existing positions closed: 199
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Canaccord Genuity William Plovanic 71% 1-year accuracy 35 / 49 met price target | 16%upside $103 | Buy Maintained | 14 Feb 2025 |
Morgan Stanley Patrick Wood 73% 1-year accuracy 8 / 11 met price target | 8%downside $82 | Equal-Weight Maintained | 14 Feb 2025 |
Redburn Atlantic Issie Kirby 25% 1-year accuracy 1 / 4 met price target | 29%upside $115 | Buy Upgraded | 3 Feb 2025 |
Baird Jeff Johnson 38% 1-year accuracy 5 / 13 met price target | 17%upside $104 | Outperform Upgraded | 16 Jan 2025 |
Citigroup Joanne Wuensch 66% 1-year accuracy 31 / 47 met price target | 2%upside $91 | Buy Maintained | 11 Dec 2024 |
Financial journalist opinion
Based on 18 articles about DXCM published over the past 30 days









